Jessica Johnson, DNP, APRN, PMHNP (BC)
Clinical Instructor of Child Psychiatric NursingCards
About
Research
Publications
2021
Systematic Review and Meta-analysis: An Empirical Approach to Defining Treatment Response and Remission in Pediatric Obsessive-Compulsive Disorder
Farhat LC, Vattimo EFQ, Ramakrishnan D, Levine JLS, Johnson JA, Artukoglu BB, Landeros-Weisenberger A, Asbahr FR, Cepeda SL, Comer JS, Fatori D, Franklin ME, Freeman JB, Geller DA, Grant PJ, Goodman WK, Heyman I, Ivarsson T, Lenhard F, Lewin AB, Li F, Merlo LJ, Mohsenabadi H, Peris TS, Piacentini J, Rosa-Alcázar AI, Rosa-Alcázar À, Rozenman M, Sapyta JJ, Serlachius E, Shabani MJ, Shavitt RG, Small BJ, Skarphedinsson G, Swedo SE, Thomsen PH, Turner C, Weidle B, Miguel EC, Storch EA, Mataix-Cols D, Bloch MH. Systematic Review and Meta-analysis: An Empirical Approach to Defining Treatment Response and Remission in Pediatric Obsessive-Compulsive Disorder. Journal Of The American Academy Of Child & Adolescent Psychiatry 2021, 61: 495-507. PMID: 34597773, DOI: 10.1016/j.jaac.2021.05.027.Peer-Reviewed Original ResearchConceptsPediatric obsessive-compulsive disorderObsessive-compulsive disorderOptimal cutoffYale-Brown ObsessiveCY-BOCSClinical trialsSystematic reviewClinical Global Impression-ImprovementRandom-effects meta-analysis modelDiscriminative abilityStandardized operational definitionsMeta-analysis modelChildren's Yale-Brown ObsessiveDiagnostic test accuracyTreatment responseRemissionSeverity ScaleMeta-AnalysisYouden indexCompulsive ScaleTrialsDisordersA Phase-2 Pilot Study of a Therapeutic Combination of Δ9-Tetrahydracannabinol and Palmitoylethanolamide for Adults With Tourette’s Syndrome
Bloch MH, Landeros-Weisenberger A, Johnson JA, Leckman JF. A Phase-2 Pilot Study of a Therapeutic Combination of Δ9-Tetrahydracannabinol and Palmitoylethanolamide for Adults With Tourette’s Syndrome. Journal Of Neuropsychiatry 2021, 33: 328-336. PMID: 34340527, DOI: 10.1176/appi.neuropsych.19080178.Peer-Reviewed Original ResearchConceptsTourette syndromeTic symptomsUncontrolled trialsYale Global Tic Severity Scale-Total Tic ScoreDouble-blind placebo-controlled trialAvailable evidence-based treatmentsPhase 2 pilot studyExtension phasePlacebo-controlled trialRefractory Tourette syndromeTotal tic scoreEffective pharmacological treatmentCannabis-derived compoundsEvidence-based treatmentsTHC dosingSecondary outcomesPrimary outcomeComorbid conditionsPharmacological treatmentTic scoreYGTSS scoresTherapeutic combinationsSide effectsTrial designSyndromeEfficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial
Dwyer JB, Landeros-Weisenberger A, Johnson JA, Londono Tobon A, Flores JM, Nasir M, Couloures K, Sanacora G, Bloch MH. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial. American Journal Of Psychiatry 2021, 178: 352-362. PMID: 33653121, DOI: 10.1176/appi.ajp.2020.20010018.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionDepression Rating ScaleIntravenous ketamineClinical trialsAdolescent treatment-resistant depressionAdult treatment-resistant depressionPlacebo-controlled clinical trialSignificant short-term efficacySerious adverse eventsPrimary outcome measureSingle intravenous infusionChildren's Depression Rating ScaleCrossover clinical trialShort-term efficacyMajor depressive disorderSingle ketamine infusionSymptoms 24 hoursLater time pointsKetamine’s safetyAdverse eventsAntidepressant medicationKetamine infusionPediatric populationSignificant morbidityIntravenous infusion
2019
N-Acetylcysteine for Pediatric Obsessive-Compulsive Disorder: A Small Pilot Study
Li F, Welling MC, Johnson JA, Coughlin C, Mulqueen J, Jakubovski E, Coury S, Landeros-Weisenberger A, Bloch MH. N-Acetylcysteine for Pediatric Obsessive-Compulsive Disorder: A Small Pilot Study. Journal Of Child And Adolescent Psychopharmacology 2019, 30: 32-37. PMID: 31800306, PMCID: PMC7133418, DOI: 10.1089/cap.2019.0041.Peer-Reviewed Original ResearchConceptsCY-BOCS total scoreN-acetylcysteineYale-Brown ObsessiveTotal scorePlacebo groupNAC groupStudy populationBenefit of NACPlacebo-controlled clinical trialSymptom severityEffect of NACMild adverse eventsOCD symptom severityLarger study populationPediatric obsessive-compulsive disorderSmall pilot studyChildren's Yale-Brown ObsessiveStudy medicationAdverse eventsPrimary outcomeGlutamate dysfunctionObsessive-compulsive disorderWeek 12Future trialsNAC treatment
2018
Systematic review and meta‐analysis: Dose–response curve of SSRIs and SNRIs in anxiety disorders
Jakubovski E, Johnson JA, Nasir M, Müller‐Vahl K, Bloch MH. Systematic review and meta‐analysis: Dose–response curve of SSRIs and SNRIs in anxiety disorders. Depression And Anxiety 2018, 36: 198-212. PMID: 30479005, DOI: 10.1002/da.22854.Peer-Reviewed Original ResearchConceptsSerotonin-norepinephrine reuptake inhibitorsSelective serotonin reuptake inhibitorsGreater treatment benefitHigh dosesTreatment responseAnxiety disordersReuptake inhibitorsSymptom improvementTreatment benefitPharmacological agentsRandomized placebo-controlled clinical trialSSRIs/serotonin-norepinephrine reuptake inhibitorsPlacebo-controlled clinical trialIndividual pharmacological agentsCochrane Central RegisterNorepinephrine reuptake inhibitorsSerotonin reuptake inhibitorsOverall symptom improvementGreater symptom improvementDose-response curveLinear mixed model analysisCentral RegisterMedication classesAdult patientsControlled Trials
2017
Meta-analysis: Risk of dry mouth with second generation antidepressants
Cappetta K, Beyer C, Johnson JA, Bloch MH. Meta-analysis: Risk of dry mouth with second generation antidepressants. Progress In Neuro-Psychopharmacology And Biological Psychiatry 2017, 84: 282-293. PMID: 29274375, DOI: 10.1016/j.pnpbp.2017.12.012.Peer-Reviewed Original ResearchConceptsDry mouthSecond-generation antidepressantsGreater riskAntidepressant agentsGeneration antidepressantsPlacebo-controlled trialPooled risk ratioStratified subgroup analysisReceptor affinity profileSNRI classMedication classesAntidepressant medicationAtypical antidepressantsRisk ratioSubgroup analysisDepressive disorderSTUDY SELECTIONPubMed searchDATA SOURCESSNRIsDiagnostic indicationsSSRIsAntidepressantsAnxiety diagnosesAnxiety disorders6.23 Predictors of Long-Term Risky Driving Behavior in the Multimodal Treatment Study of Children With Attention-Deficit/Hyperactivity Disorder (ADHD)
Johnson J, Jakubovski E, Reed M, Bloch M. 6.23 Predictors of Long-Term Risky Driving Behavior in the Multimodal Treatment Study of Children With Attention-Deficit/Hyperactivity Disorder (ADHD). Journal Of The American Academy Of Child & Adolescent Psychiatry 2017, 56: s284. DOI: 10.1016/j.jaac.2017.09.368.Peer-Reviewed Original ResearchEfficacy of antipsychotics for irritability and aggression in children: a meta-analysis
van Schalkwyk GI, Lewis AS, Beyer C, Johnson J, van Rensburg S, Bloch MH. Efficacy of antipsychotics for irritability and aggression in children: a meta-analysis. Expert Review Of Neurotherapeutics 2017, 17: 1045-1053. PMID: 28847182, DOI: 10.1080/14737175.2017.1371012.Peer-Reviewed Original ResearchConceptsDegree of sedationSubgroup analysisDiagnostic indicationsOverall dose effectEfficacy of risperidoneStratified subgroup analysisEfficacy of antipsychoticsIndividual antipsychotic agentsChoice of agentRange of diagnosesSpecific medicationsAntipsychotic efficacyAntipsychotic agentsAntipsychotic doseClinical dataOverall effect sizeAntipsychoticsNegative psychosocial outcomesIrritabilityPsychosocial outcomesEfficacyDiagnosisDose effectSedationRisperidoneMeta‐analysis: Risk of hyperhidrosis with second‐generation antidepressants
Beyer C, Cappetta K, Johnson JA, Bloch MH. Meta‐analysis: Risk of hyperhidrosis with second‐generation antidepressants. Depression And Anxiety 2017, 34: 1134-1146. PMID: 28881483, DOI: 10.1002/da.22680.Peer-Reviewed Original ResearchConceptsSSRI/SNRI medicationsSerotonin-norepinephrine reuptake inhibitorsSecond-generation antidepressantsAntidepressant medicationSNRI medicationsMost antidepressant medicationsPlacebo-controlled trialPooled risk ratioStratified subgroup analysisTreatment of adultsReceptor affinity profileMedication classesReuptake inhibitorsMedication typeObsessive-compulsive disorderAntidepressant agentsRisk ratioSubgroup analysisDepressive disorderDopamine transporter affinityHyperhidrosisMedicationsPubMed searchSide effectsDopamine transporterKetamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial
Taylor JH, Landeros-Weisenberger A, Coughlin C, Mulqueen J, Johnson JA, Gabriel D, Reed MO, Jakubovski E, Bloch MH. Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial. Neuropsychopharmacology 2017, 43: 325-333. PMID: 28849779, PMCID: PMC5729569, DOI: 10.1038/npp.2017.194.Peer-Reviewed Original ResearchConceptsLiebowitz Social Anxiety ScaleSocial anxiety disorderAnxiety disordersSocial Anxiety ScaleSelf-reported anxietySocial phobia symptomsRatings of anxietyPotent N-methyl-d-aspartate receptor antagonistPhobia symptomsAnxiety symptomsAnxiety ScaleImpact of ketamineInitial evidenceAnxietyTreatment respondersVAS anxietyPlacebo-controlled crossover trialRatingsDisordersLinear mixed modelsPrior studiesConcept trialInadequate symptom reliefRandom orderMixed models
News
Get In Touch
Contacts
Academic Office Number
Appointment Number
Office Fax Number
Clinic Fax Number
Locations
350 George Street
Academic Office
New Haven, CT 06511